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enucleation is employed quite frequently even at institutions
that do not support its ubiquitous use. These data lay the
groundwork for determining whether RT is a modifiable
variable for functional and oncologic outcomes in patients
who undergo NSS. 
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Aim: The aim of this study was to analyse the intra- and post-
operative complications, as well as the predictive factors of
Trifecta outcome in patients submitted to endoscopic robot-
assisted simple enucleation (ERASE) and open simple
enucleation (OSE) for clinical T1 renal masses. Materials and
Methods: Overall, 634 cases treated with OSE (n=290) and
ERASE (n=344) were prospectively recorded in our
Department between 2006 and 2014. Trifecta was defined as
simultaneous ischemia time <25 min, no surgical
complication and negative surgical margin. A univariate
analysis and multivariate logistic regression were performed
for Trifecta. Results: The two groups were comparable for
body mass index (BMI), comorbidity, tumor side, clinical T
score, tumor diameter, surgical indication, pre-operative renal
function, pre-operative hemoglobin and hematocrit. A
significant difference was found between the OSE and the
ERASE groups in operative time (115 (96-130) vs. 150 (120-
180) minutes, p<0.0001), pedicle clamping (93.8% vs.
69.2%, p<0.0001), estimated blood loss (EBL) (150 (100-
200) vs. 100 (100-143) cc, p<0.0001) and intraoperative
complications (3.4% vs. 1.7%, p=0.02). The two groups were
comparable for warm ischemia time (WIT) ≥25 min. A
significant difference was found between OSE and ERASE
in overall (16.6% vs. 5.5%, p<0.0001), Clavien 2 (11.7% vs.
4.4%, p=0.02) and Clavien 3 (3.1% vs. 1.7%, p=0.04) post-
operative surgical complications, length of stay (6.0 (5.0-7.0)
vs. 5.0 (4.0-6.0) days, p<0.0001), pre-operative 1st day delta
creatinine (0.3 (0.2-0.4) vs. 0.15 (0.1-0.2) mg/dl, p<0.0001),
positive surgical margins (2.1% vs. 1.5%, p=0.04), and
Trifecta achievement (73.8% vs. 85.5%, p<0.0001). At
univariate analysis, a higher median clinical diameter, a
higher mean age, a higher median Charlson comorbidity
index (CCI), endophytic tumor growth pattern, renal sinus
and calyceal dislocation of the tumor, a higher median
PADUA score and OSE were predictive factors of Trifecta
achievement. At multivariate analysis, CCI lost significance
(p=0.26), while age (odds ratio (OR)=1.02, 95% confidence
interval (95% CI)=1.00-1.04, p=0.001), clinical diameter
(OR=1.22, CI=1.05-1.42, p=0.008), PADUA score (OR=1.23,
CI=1.07-1.41, p=0.004) and OSE (OR=1.74, CI=1.13-2.68,
p=0.01) were confirmed predictive factors for Trifecta failure.
Conclusion: The ERASE is a feasible and safe technique,
which shows a comparable WIT, together with a significantly
lower EBL, surgical complications’ rate, length of stay and a
significantly higher Trifecta achievement compared to OSE.
Age, comorbidity, tumor diameter and PADUA score, in
association with surgical approach, represent significant
predictive factors of Trifecta failure.
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